Nanocrystals for the parenteral delivery of poorly water-soluble drugs

Current Opinion in Solid State and Materials Science

Volumn 16, Issue 6, 2012, Pages 295-301

  Sun, Bo ^a   Yeo, Yoon ^a,b,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

Nanocrystals; Nanosuspension; Parenteral applications; Poorly water soluble drugs

Indexed keywords

NANOCRYSTALS;

BOTTOM UP; NANO-SUSPENSIONS; PHARMACEUTICAL INDUSTRY; POORLY WATER-SOLUBLE DRUGS; THERAPEUTIC APPLICATION; TOPDOWN;

DRUG DELIVERY;

EID: 84875242104     PISSN: 13590286     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cossms.2012.10.004     Document Type: Review

References (96)

1. E.M. Merisko-Liversidge, and G.G. Liversidge Drug nanoparticles: formulating poorly water-soluble compounds Toxicol Pathol 36 2008 43 48
2. B.E. Rabinow Nanosuspensions in drug delivery Nat Rev Drug Discov 3 2004 785 796
3. Emilio Squillante, and S. Sethia Solid dispersions: revival with greater possibilities and applications in oral drug delivery Crit Rev Ther Drug Carrier Syst 20 2003 34
4. S. He, Z. Cui, D. Mei, H. Zhang, X. Wang, and W. Dai A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo AAPS Pharm Sci Technol 13 2012 846 852
5. W. Bouquet, W. Ceelen, B. Fritzinger, P. Pattyn, M. Peeters, and J.P. Remon Paclitaxel/β-cyclodextrin complexes for hyperthermic peritoneal perfusion-formulation and stability Eur J Pharm Biopharm 66 2007 391 397
6. H. Chen, L. Tang, Y. Qin, Y. Yin, J. Tang, and W. Tang Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery Eur J Pharm Biopharm 40 2010 94 102
7. K. Shao, R. Huang, J. Li, L. Han, L. Ye, and J. Lou Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain J Control Release 147 2010 118 126
8. Y. Gong, Y. Wu, C. Zheng, L. Fan, F. Xiong, and J. Zhu An excellent delivery system for improving the oral bioavailability of natural vitamin E in rats AAPS Pharm Sci Technol 13 2012 961 966
9. S.S. Dodiya, S.S. Chavhan, K.K. Sawant, and A.G. Korde Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies J Microencapsul 28 2011 515 527
10. E. Gullotti, and Y. Yeo Beyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles J Control Release 2012 10.1016/j.jconrel.2012.04.042
11. V.B. Patravale, A.A. Date, and R.M. Kulkarni Nanosuspensions: a promising drug delivery strategy J. Pharm. Pharmacol. 56 2004 827 840
12. W. Sun, S. Mao, Y. Shi, L.C. Li, and L. Fang Nanonization of itraconazole by high pressure homogenization: Stabilizer optimization and effect of particle size on oral absorption J Pharm Sci 100 2011 3365 3373
13. K. Mitri, R. Shegokar, S. Gohla, C. Anselmi, and R.H. Müller Lutein nanocrystals as antioxidant formulation for oral and dermal delivery Int J Pharm 420 2011 141 146
14. J. Zhang, H. Lv, K. Jiang, and Y. Gao Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal Int J Pharm 420 2011 180 188
15. S. Ganta, J.W. Paxton, B.C. Baguley, and S. Garg Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery Int J Pharm 367 2009 179 186
16. H. Zhang, C.P. Hollis, Q. Zhang, and T. Li Preparation and antitumor study of camptothecin nanocrystals Int J Pharm 415 2011 293 300
17. L. De Smet, P. Colin, W. Ceelen, M. Bracke, J. Van Bocxlaer, and J. Remon Development of a nanocrystalline paclitaxel formulation for Hipec treatment Pharm Res 29 2012 2398 2406
18. R.H. Müller, S. Gohla, and C.M. Keck State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery Eur J Pharm Biopharm 78 2011 1 9
19. Y. Barenholz Doxil® - the first FDA-approved nano-drug: lessons learned J Control Release 160 2012 117 134
20. S. Xiong, B. Yu, J. Wu, H. Li, and R.J. Lee Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS Biomed Pharmacother 65 2011 2 8
21. A.J. Montero, B. Adams, C.M. Diaz-Montero, and S. Glück Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review Expert Rev Clin Pharmacol 4 2011 329 334
22. H.-K. Chan, and P.C.L. Kwok Production methods for nanodrug particles using the bottom-up approach Adv Drug Deliv Rev 63 2011 406 416
23. L. Lindfors, P. Skantze, U. Skantze, J. Westergren, and U. Olsson Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth Langmuir 23 2007 9866 9874
24. A.G. Thombre, J.C. Shah, K. Sagawa, and W.B. Caldwell In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations Int J Pharm 428 2012 8 17
25. R. Shegokar, and R.H. Müller Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives Int J Pharm 399 2010 129 139
26. J. Hu, W.K. Ng, Y. Dong, S. Shen, and R.B.H. Tan Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying Int J Pharm 404 2011 198 204
27. H. de Waard, N. Grasmeijer, W.L.J. Hinrichs, A.C. Eissens, P.P.F. Pfaffenbach, and H.W. Frijlink Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production Eur J Pharm Sci 38 2009 224 229
28. H. de Waard, W.L.J. Hinrichs, and H.W. Frijlink A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying J Control Release 128 2008 179 183
29. E. Merisko-Liversidge, and G.G. Liversidge Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology Adv Drug Deliv Rev 63 2011 427 440
30. C.M. Keck, and R.H. Müller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur J Pharm Biopharm 62 2006 3 16
31. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly-water-soluble compounds Eur J Pharm Biopharm 18 2003 113 120
32. M. Juhnke, D. Märtin, and E. John Generation of wear during the production of drug nanosuspensions by wet media milling Eur J Pharm Biopharm 81 2012 214 222
33. P. Begat, P.M. Young, S. Edge, J.S. Kaerger, and R. Price The effect of mechanical processing on surface stability of pharmaceutical powders: visualization by atomic force microscopy J Pharm Sci 92 2003 611 620
34. B. Van Eerdenbrugh, G. Van den Mooter, and P. Augustijns Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products Int J Pharm 364 2008 64 75
35. S.L. Raghavan, A. Trividic, A.F. Davis, and J. Hadgraft Crystallization of hydrocortisone acetate: influence of polymers Int J Pharm 212 2001 213 221
36. S.L. Raghavan, K. Schuessel, A. Davis, and J. Hadgraft Formation and stabilisation of triclosan colloidal suspensions using supersaturated systems Int J Pharm 261 2003 153 158
37. J.M. Dintaman, and J.A. Silverman Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) Pharm Res 16 1999 1550 1556
38. Y. Liu, L. Huang, and F. Liu Paclitaxel nanocrystals for overcoming multidrug resistance in cancer Mol Pharm 7 2010 863 869
39. B. Van Eerdenbrugh, J. Vermant, J.A. Martens, L. Froyen, J. Van Humbeeck, and P. Augustijns A screening study of surface stabilization during the production of drug nanocrystals J Pharm Sci 98 2009 2091 2103
40. S. Verma, R. Gokhale, and D.J. Burgess A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions Int J Pharm 380 2009 216 222
41. L. Gao, D. Zhang, M. Chen, T. Zheng, and S. Wang Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement Drug Dev Ind Pharm 33 2007 1332 1339
42. J. Deng, L. Huang, and F. Liu Understanding the structure and stability of paclitaxel nanocrystals Int J Pharm 390 2010 242 249
43. Z. Deng, S. Xu, and S. Li Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications Int J Pharm 351 2008 236 243
44. P.R. Mishra, L.A. Shaal, R.H. Müller, and C.M. Keck Production and characterization of Hesperetin nanosuspensions for dermal delivery Int J Pharm 371 2009 182 189
45. H. Piao, N. Kamiya, A. Hirata, T. Fujii, and M. Goto A novel solid-in-oil nanosuspension for transdermal delivery of diclofenac sodium Pharm Res 25 2008 896 901
46. H. Piao, N. Kamiya, J. Watanabe, H. Yokoyama, A. Hirata, and T. Fujii Oral delivery of diclofenac sodium using a novel solid-in-oil suspension Int J Pharm 313 2006 159 162
47. K. Adibkia, Y. Javadzadeh, S. Dastmalchi, G. Mohammadi, F.K. Niri, and M. Alaei-Beirami Naproxen-eudragit® RS100 nanoparticles: preparation and physicochemical characterization Colloids Surf 83B 2011 155 159
48. R. Pignatello, C. Bucolo, P. Ferrara, A. Maltese, A. Puleo, and G. Puglisi Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen Eur J Pharmacol Sci 16 2002 53 61
49. R. Pignatello, C. Bucolo, and G. Puglisi Ocular tolerability of Eudragit RS100® and RL100® nanosuspensions as carriers for ophthalmic controlled drug delivery J Pharm Sci 91 2002 2636 2641
50. J. Araújo, E. Gonzalez, M.A. Egea, M.L. Garcia, and E.B. Souto Nanomedicines for ocular NSAIDs: safety on drug delivery Nanomedicine: NBM 5 2009 394 401
51. M.A. Kassem, A.A. Abdel Rahman, M.M. Ghorab, M.B. Ahmed, and R.M. Khalil Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs Int J Pharm 340 2007 126 133
52. H.S.M. Ali, P. York, A.M.A. Ali, and N. Blagden Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling J Control Release 149 2011 175 181
53. H.S.M. Ali, P. York, and N. Blagden Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors Int J Pharm 375 2009 107 113
54. C. Jacobs, and R.H. Müller Production and characterization of a budesonide nanosuspension for pulmonary administration Pharm Res 19 2002 189 194
55. W.K. Kraft, B. Steiger, D. Beussink, J.N. Quiring, N. Fitzgerald, and H.E. Greenberg The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers J Clin Pharmacol 44 2004 67 72
56. R. Zhao, C.P. Hollis, H. Zhang, L. Sun, R.A. Gemeinhart, and T. Li Hybrid nanocrystals: achieving concurrent therapeutic and bioimaging functionalities toward solid tumors Mol Pharm 8 2011 1985 1991
57. F. Liu, J.-Y. Park, Y. Zhang, C. Conwell, Y. Liu, and S.R. Bathula Targeted cancer therapy with novel high drug-loading nanocrystals J Pharm Sci 99 2010 3542 3551
58. L. Yao, X. Zhao, Q. Li, Y. Zu, Y. Fu, and B. Zu In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity Int J Pharm 423 2012 586 588
59. Y. Wang, Z. Liu, D. Zhang, X. Gao, X. Zhang, and C. Duan Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension Colloids Surf 83B 2011 189 197
60. L. Gao, D. Zhang, M. Chen, C. Duan, W. Dai, and L. Jia Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions Int J Pharm 355 2008 321 327
61. H. Lou, L. Gao, X. Wei, Z. Zhang, Zheng D, and D. Zhang Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice Colloids Surf 87B 2011 319 325
62. Y. Gao, Z. Li, M. Sun, H. Li, C. Guo, and J. Cui Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer Drug Dev Ind Pharm 36 2010 1225 1234
63. R. Shegokar, and K.K. Singh Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation Int J Pharm 421 2011 341 352
64. H.M. Shubar, I.R. Dunay, S. Lachenmaier, M. Dathe, F.N. Bushrab, and R. Mauludin The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis J Drug Target 17 2009 257 267
65. H.M. Shubar, S. Lachenmaier, M.M. Heimesaat, U. Lohman, R. Mauludin, and R.H. Mueller SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers J Drug Target 19 2011 114 124
66. G. Bajaj, and Y. Yeo Drug delivery systems for intraperitoneal therapy Pharm Res 27 2010 735 738
67. P. Marchettini, O.A. Stuart, F. Mohamed, D. Yoo, and P.H. Sugarbaker Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model Cancer Chemoth Pharm 49 2002 499 503
68. F. Mohamed, O.A. Stuart, and P.H. Sugarbaker Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions J Surg Res 113 2003 114 120
69. R.J. Morgan, J.H. Doroshow, T. Synold, D. Lim, S. Shibata, and K. Margolin Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics Clin Cancer Res 9 2003 5896 5901
70. E. de Bree, H. Rosing, J.H. Beijnen, J. Romanos, J. Michalakis, and V. Georgoulias Anti-Cancer Drug 14 2003 103 110
71. L.S. Hofstra, A.M.E. Bos, E.G.E. de Vries, A.G.J. van der Zee, A.T.M. Willemsen, and H. Rosing Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer Gynecol Oncol 85 2002 517 523
72. A.J. Witkamp, E. de Bree, A.R. Van Goethem, and F.A.N. Zoetmulder Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy Cancer Treat Rev 27 2001 365 374
73. M. Markman, E. Rowinsky, T. Hakes, B. Reichman, W. Jones, and J.L. Lewis Phase-I trial of intraperitoneal taxol-a gynecologic oncology group-study J Clin Oncol 10 1992 1485 1491
74. S.K. Chambers, H.-H.S. Chow, M.F. Janicek, J.M. Cragun, K.D. Hatch, and H. Cui Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer Clin Cancer Res 18 2012 2668 2678
75. C. Hasovits, and S. Clarke Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics Clin Pharmacokinet 51 2012 203 224
76. Z. Lu, J. Wang, M.G. Wientjes, and J.L.S. Au Intraperitoneal therapy for peritoneal cancer Future Oncol 6 2010 1625 1641
77. R.L. Dedrick, C.E. Myers, P.M. Bungay, and V.T. DeVita Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer Treat Rep 62 1978 1 11
78. M. Markman Intraperitoneal drug delivery of antineoplastics Drugs 61 2001 1057 1065
79. A. Nissan, A. Stojadinovic, A. Garofalo, J. Esquivel, and P. Piso Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present, and future J Surg Oncol 100 2009 335 344
80. P. Zahedi, J. Stewart, R. De Souza, M. Piquette-Miller, and C. Allen An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels J Control Release 158 2012 379 385
81. M. Markman Intraperitoneal antineoplastic drug delivery: rationale and results Lancet Oncol 4 2003 277 283
82. K. Hirano, and C.A. Hunt Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration J Pharm Sci 74 1985 915 921
83. H. Lu, B. Li, Y. Kang, W. Jiang, Q. Huang, and Q. Chen Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting Cancer Chemother Pharm 59 2007 175 181
84. J.H. Yao, K.R. Elder, H. Guo, and M. Grant Theory and simulation of Ostwald ripening Phys Rev B. 47 1993 14110 14125
85. S. Verma, S. Kumar, R. Gokhale, and D.J. Burgess Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening Int J Pharm 406 2011 145 152
86. L. Lindfors, P. Skantze, U. Skantze, M. Rasmusson, A. Zackrisson, and U. Olsson Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening Langmuir 22 2005 906 910
87. M.B.J. Meinders, and T. van Vliet The role of interfacial rheological properties on Ostwald ripening in emulsions Adv Colloid Interface 108-109 2004 119 126
88. P. Walstra Formation of emulsions P. Becher, Encyclopedia of emulsion technology: volume 1-basic theory 1983 Marcel Dekker New York 57 128
89. D.S. Singare, S. Marella, K. Gowthamrajan, G.T. Kulkarni, R. Vooturi, and P.S. Rao Optimization of formulation and process variable of nanosuspension: an industrial perspective Int J Pharm 402 2010 213 220
90. B. Van Eerdenbrugh, L. Froyen, J. Van Humbeeck, J.A. Martens, P. Augustijns, and G. Van den Mooter Drying of crystalline drug nanosuspensions - The importance of surface hydrophobicity on dissolution behavior upon redispersion Eur J Pharmacol Sci 35 2008 127 135
91. G. Bajaj, M.R. Kim, S.I. Mohammed, and Y. Yeo Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors J Control Release 158 2012 386 392
92. A. Dolenc, J. Kristl, S. Baumgartner, and O. Planinšek Advantages of celecoxib nanosuspension formulation and transformation into tablets Int J Pharm 376 2009 204 212
93. R. Ambrus, P. Kocbek, J. Kristl, R. Šibanc, R. Rajkó, and P. Szabó-Révész Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam Int J Pharm 381 2009 153 159
94. M. Kakran, N.G. Sahoo, L. Li, Z. Judeh, Y. Wang, and K. Chong Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension Int J Pharm 383 2010 285 292
95. D. Xia, P. Quan, H. Piao, H. Piao, S. Sun, and Y. Yin Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability Eur J Pharm Sci 40 2010 325 334
96. L. Gao, G. Liu, X. Wang, F. Liu, Y. Xu, and J. Ma Preparation of a chemically stable quercetin formulation using nanosuspension technology Int J Pharm 404 2011 231 237